3,652 results match your criteria: "Hereditary Angioedema"

Real-world Effectiveness of Lanadelumab in Hereditary Angioedema: Multi-country INTEGRATED Observational Study.

J Allergy Clin Immunol Pract

December 2024

EUCAN Medical Affairs, Takeda Pharmaceuticals International AG, Glattpark-Opfikon (Zürich), Switzerland.

Background: Hereditary angioedema (HAE) is a rare genetic disease characterized by recurrent episodes of cutaneous or subcutaneous edema. There is clinical need for treatments that reduce the rate of HAE attacks in patients.

Objectives: Primary objectives were to evaluate the effectiveness of lanadelumab on attack free rate (AFR; proportion of patients who had zero HAE attacks), and on every two weeks (Q2W) and every four weeks (Q4W) adjustments on AFR.

View Article and Find Full Text PDF

Background: Hereditary angioedema (HAE) is clinically characterized by recurrent attacks of cutaneous and submucosal swelling.

Objective: To investigate real-world timing, potential barriers, and impact of delaying on-demand treatment (OD) of HAE attacks METHODS: Patients with HAE (type I or II) aged ≥12 years with ≥1 treated (Treated Cohort) or untreated (Untreated Cohort) attack in the past 3 months were recruited by the US HAE Association. Respondents completed a 20-minute, self-reported, online survey about their last HAE attack.

View Article and Find Full Text PDF

Clinical Response and Corresponding Blood Transcriptome Pathways Pre- And Post-Treatment Of Hereditary Angioedema Prodromes Compared To Active Swelling Attacks.

J Allergy Clin Immunol

December 2024

University of Cincinnati College of Medicine, Department of Internal Medicine, Division of Rheumatology, Allergy and Immunology, Cincinnati, Ohio; Bernstein Allergy Group, LLC and Bernstein Clinical Research Center, LLC. Electronic address:

Rationale: Approximately 85% Hereditary angioedema (HAE) attacks are associated with prodromal symptoms. We investigated the clinical effect of treating HAE-C1 inhibitor (HAE-C1INH) Type 1 patients with Conestat Alfa® (recombinant human C1-INH) during their prodrome versus an active swelling episode and associated changes in blood transcriptomic genes and pathways pre- vs. post-treatment.

View Article and Find Full Text PDF

Study of Urinary Protein Biomarkers in Hereditary Angioedema.

J Investig Allergol Clin Immunol

December 2024

Department of Allergy and Clinical Immunology, National Clinical Research Center for Immunologic Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.

Background: Hereditary angioedema (HAE) is a rare and potentially life-threatening disease, and diagnosis is often missed or delayed. We aimed to identify noninvasive urinary protein biomarkers and to evaluate their potential roles in diagnosis and evaluation of disease severity.

Methods: Using data-independent acquisition (DIA)-based urinary proteomics, we identified proteins that were differentially expressed between patients with HAE and healthy control (HC) groups.

View Article and Find Full Text PDF

Hereditary angioedema with C1 inhibitor deficiency (HAE-C1-INH) is a rare disorder characterized by recurrent, potentially life-threatening swelling in various parts of the body, including the limbs, face, and airways Current treatments focus primarily on symptomatic relief and the management of acute attacks, without targeting the underlying genetic cause or the dysregulated bradykinin production. Donidalorsen, a novel antisense oligonucleotide, addresses a key driver of HAE-C1-INH by targeting prekallikrein (PKK) to reduce bradykinin levels. This meta-analysis evaluates the efficacy and safety of Donidalorsen versus placebo, focusing on two dosing regimens: 4-week and 8-week intervals.

View Article and Find Full Text PDF

New drugs for the treatment of hereditary angioedema.

Expert Opin Biol Ther

December 2024

Department of Medical Sciences and Public Health, University of Cagliari, Cagliari, Italy.

Article Synopsis
  • Revolutionary drugs have emerged in the last 5 years for hereditary angioedema (HAE), leading to better symptom control and improved quality of life for patients through innovative self-administered therapies.
  • This review details currently approved treatments for HAE and future therapies under development, emphasizing advancements in understanding the disease's pathophysiology.
  • New long-term prophylactic treatments and oral on-demand options aim to create personalized treatment plans, potentially allowing for attack-free remission and enhanced overall patient care.
View Article and Find Full Text PDF

Hereditary angioedema in children: Review and practical perspective for clinical management.

Pediatr Allergy Immunol

December 2024

French National Reference Center for Angioedema (CREAK), Center of Excellence and Reference (ACARE), Internal Medicine Department, Grenoble Alpes University Hospital, Grenoble, France.

Background: Hereditary angioedema (HAE) in children has specific features and requires multidisciplinary management.

Methods: We performed a literature search and underwent in-depth discussions to provide practical tools for physicians.

Results: HAE is a rare, life-threatening genetic disorder.

View Article and Find Full Text PDF

Angioedema.

Allergy Asthma Clin Immunol

December 2024

Division of Allergy and Immunology, Department of Medicine, Western University, London, ON, Canada.

Angioedema can occur in the absence of urticaria and can be broadly divided into three main categories: mast cell-mediated (e.g., histamine), non-mast-cell-mediated (bradykinin-induced) and idiopathic angioedema.

View Article and Find Full Text PDF

Pregnancy revealing hereditary angioedema type III with factor XII mutation managed in a resource-limited setting with no C1-inhibitor concentrate availability: a case report.

Int J Obstet Anesth

October 2024

Department of Dermatology, Venerology and Allergology, CHU Mohammed VI, Oujda, Morocco; Laboratory of Epidemiology, Clinical Research and Public Health. Faculty of Medicine and Pharmacy, Mohammed Premier University, Oujda, Morocco.

View Article and Find Full Text PDF
Article Synopsis
  • Targeted therapies using biologics for atopic diseases, urticaria, and angioedema are advancing quickly, with several new antibodies developed, tested, and approved for clinical use, like omalizumab and dupilumab.
  • There is ongoing research into combining different biologics for enhanced treatment efficacy, expanding their applications to conditions like food allergies and eosinophilic esophagitis.
  • There are emerging concerns about unexpected side effects and hypersensitivity reactions associated with these therapies, raising important questions about their safety and mechanisms, particularly in specific patient groups like children.
View Article and Find Full Text PDF

Genital Attacks in Hereditary Angioedema and Their Effects on Sexual Life.

Medicina (Kaunas)

October 2024

Department of Internal Medicine, Division of Immunology and Allergy, Faculty of Medicine, Ege University, Izmir 35100, Turkey.

Article Synopsis
View Article and Find Full Text PDF

Omics analysis reveals galectin-3 to be a potential key regulator of allergic inflammation in hereditary angioedema.

J Allergy Clin Immunol Glob

February 2025

Department of Medicine, Division of Allergy, Immunology & Rheumatology, Jacobs School of Medicine and Biomedical Sciences, Clinical Translational Research Center, University at Buffalo, Buffalo, NY.

Article Synopsis
View Article and Find Full Text PDF

Successful lanadelumab dose spacing in type I hereditary angioedema.

Clin Exp Dermatol

November 2024

Department of Dermatology and Venereology. Coimbra Local Health Unit, Coimbra, Portugal.

View Article and Find Full Text PDF

Novel Plasma Kallikrein Inhibitors for Treating Multiple Diseases.

ACS Med Chem Lett

November 2024

Smith, Gambrell & Russell LLP, 1105 W. Peachtree Street NE, Suite 1000, Atlanta, Georgia 30309, United States.

Article Synopsis
View Article and Find Full Text PDF

COVID-19 and severe cutaneous allergic reactions to sulfonamides.

Allergy Asthma Proc

November 2024

From the Section of Allergy, Asthma and Immunology, Department of Medicine, Pennsylvania State College of Medicine, Hershey, Pennsylvania and.

Article Synopsis
View Article and Find Full Text PDF